Prescription drugs; creating the Insulin Access and Affordability Program; requiring certain financial support and agreement. Effective date. Emergency.

The document structure changed from a standard enrolled format to a floor substitute format, adding page numbers and a specific section number (60-2-3807) for the statute.

The header information was updated to reflect the 2nd Session of the 60th Legislature (2026) and identify the document as a floor substitute.

Standard enrolled act headers indicating Senate and House passage dates were replaced with the new floor substitute formatting.

Added signatures and dates for the House of Representatives and the Governor, converting the bill from a draft version to the final enrolled version ready for printing.

Updated the list of bill sponsors to include three additional House members (Waldron, Menz, and Archer) who joined the original Senate and House sponsors.

Eligibility for funding was expanded from a single nonprofit manufacturer to one or more pharmaceutical manufacturers that are developing or manufacturing fast-acting biosimilar insulin.

A new requirement was added mandating that any fast-acting biosimilar insulin receiving state funds must be manufactured in the United States.

New annual reporting requirements were established, requiring manufacturers to submit progress reports to the Department of Health, which must then compile and submit a consolidated report to the Governor and legislative leaders.

The Memorandum of Understanding (MOU) requirements were updated to include a specific timeline for production and a commitment to domestic manufacturing, replacing the previous focus solely on nonprofit status.

New sponsors (Mann, Hicks, and Stinson) were added to the bill text, and the document was finalized with passage dates and signatures from legislative presiding officers.